40
Participants
Start Date
July 2, 2020
Primary Completion Date
August 30, 2021
Study Completion Date
August 4, 2024
Nivolumab and Ipilimumab
"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
Centre François Baclesse, Caen
Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie, CARIO-HPCA, Plérin
Institut Claudius Regaud IUCT-O, Toulouse
Institut Jean Godinot, Reims
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
Centre Léon Bérard, Lyon
Groupe Hospitalier Diaconesses - Croix Saint-Simon, Paris
Institut Curie, Paris
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
ARCAGY/ GINECO GROUP
OTHER